Colin A. Flaveny

3.7k citations

34 papers · 2.8k indexed · 2 hit papers · h-index 22

Molecular Biology top 10%
Immunology top 5%
Cancer Research top 5%
Health, Toxicology and Mutagenesis top 2%
Biological Psychiatry top 0.5%

Co-authors: Gary H. Perdew Iain A. Murray Brett C. DiNatale Jennifer C. Schroeder Elizabeth M. Laurenzana Curtis J. Omiecinski Albert E. Parker Russell D. Romeo
Topics: Toxic Organic Pollutants Impact (8 papers)Cancer, Hypoxia, and Metabolism (5 papers)Muscle Physiology and Disorders (4 papers)
Cited by: Biological Psychiatry Behavioral Neuroscience Hematology
Journals: Science PLoS ONE Biochemistry
Partner nations: United States India Switzerland

In The Last Decade

Colin A. Flaveny

33 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells

2010 772 citations Anthony E. Boitano, Jian Wang et al. Science profile →
Kynurenic Acid Is a Potent Endogenous Aryl Hydrocarbon Receptor Ligand that Synergistically Induces Interleukin-6 in the Presence of Inflammatory Signaling

2010 506 citations Brett C. DiNatale, Iain A. Murray et al. profile →

Peers

Countries citing papers authored by Colin A. Flaveny

Since Specialization

Citations

This map shows the geographic impact of Colin A. Flaveny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colin A. Flaveny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colin A. Flaveny more than expected).

Fields of papers citing papers by Colin A. Flaveny

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colin A. Flaveny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colin A. Flaveny. The network helps show where Colin A. Flaveny may publish in the future.

Co-authorship network of co-authors of Colin A. Flaveny

This figure shows the co-authorship network connecting the top 25 collaborators of Colin A. Flaveny. A scholar is included among the top collaborators of Colin A. Flaveny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colin A. Flaveny. Colin A. Flaveny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	STAT1 Drives the Interferon-Like Response and Aging Hallmarks in Progeria 2023 ·PubMed ·Susana Gonzalo,(unknown),Elena V. Shashkova,Colin A. Flaveny,Ángel Baldán,Kyle S. McCommis	3
2	A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis 2021 ·PLoS ONE ·(unknown),(unknown),(unknown),(unknown),Arindam Chatterjee,Kristine Griffett,Thomas P. Burris,Colin A. Flaveny	9
3	Rev-erbα heterozygosity produces a dose-dependent phenotypic advantage in mice 2020 ·PLoS ONE ·Ryan D. Welch,Cyrielle Billon,(unknown),Thomas P. Burris,Colin A. Flaveny	5
4	LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer 2019 ·Scientific Reports ·Katherine J. Carpenter,(unknown),(unknown),Arindam Chatterjee,(unknown),(unknown),(unknown),(unknown),Laurie P. Shornick,Jinsong Zhang,Colin A. Flaveny	53
5	Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract 2019 ·Cell Communication and Signaling ·Subhayan Sur,Hiroshi Nakanishi,Colin A. Flaveny,Joseph E. Ippolito,Jane McHowat,David A. Ford,Ratna B. Ray	56
6	Rev-Erb co-regulates muscle regeneration via tethered interaction with the NF-Y cistrome 2017 ·Molecular Metabolism ·Ryan D. Welch,Chun Guo,(unknown),Katherine J. Carpenter,Natalie Stephens,(unknown),Marvin J. Meyers,Lauren M. Sparks,Steven R. Smith,Jinsong Zhang,Thomas P. Burris,Colin A. Flaveny	22
7	REV-ERB and ROR: therapeutic targets for treating myopathies 2017 ·Physical Biology ·Ryan D. Welch,Colin A. Flaveny	7
8	Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle 2017 ·Scientific Reports ·Ryan D. Welch,Cyrielle Billon,(unknown),Thomas P. Burris,Colin A. Flaveny	31
9	Fluorophore-NanoLuc BRET Reporters Enable Sensitive In Vivo Optical Imaging and Flow Cytometry for Monitoring Tumorigenesis 2015 ·Cancer Research ·Franz X. Schaub,Md. Shamim Reza,Colin A. Flaveny,Weimin Li,(unknown),Sany Hoxha,Min Guo,John L. Cleveland,Antonio L. Amelio	92
10	Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis 2015 ·Cancer Cell ·Colin A. Flaveny,Kristine Griffett,Bahaa Elgendy,Melissa Kazantzis,(unknown),Antonio L. Amelio,Arindam Chatterjee,John K. Walker,Laura A. Solt,Theodore M. Kamenecka,Thomas P. Burris	160
11	The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis 2015 ·Molecular Metabolism ·Kristine Griffett,Ryan D. Welch,Colin A. Flaveny,Grant R. Kolar,Brent A. Neuschwander‐Tetri,Thomas P. Burris	66
12	Pyrvinium Attenuates Hedgehog Signaling Downstream of Smoothened 2014 ·Cancer Research ·Bin Li,Dennis Liang Fei,Colin A. Flaveny,Nadia Dahmane,Valérie Baubet,Zhiqiang Wang,Feng Bai,Xin‐Hai Pei,Jezabel Rodríguez‐Blanco,Brian Hang,Darren Orton,Lu Han,Baolin Wang,Anthony J. Capobianco,Ethan Lee,David J. Robbins	65
13	Repurposing the FDA-Approved Pinworm Drug Pyrvinium as a Novel Chemotherapeutic Agent for Intestinal Polyposis 2014 ·PLoS ONE ·Bin Li,Colin A. Flaveny,Camilla Giambelli,Dennis Liang Fei,Lu Han,Brian Hang,Feng Bai,Xin‐Hai Pei,Vânia Nosé,(unknown),Anthony J. Capobianco,Darren Orton,Ethan Lee,David J. Robbins	53
14	Hedgehog Signaling Regulates Bladder Cancer Growth and Tumorigenicity 2012 ·Cancer Research ·Dennis Liang Fei,Avencia Sánchez-Mejías,Zhiqiang Wang,Colin A. Flaveny,Jun Long,Samer Singh,Jezabel Rodríguez‐Blanco,Robert Tokhunts,Camilla Giambelli,Karoline J. Briegel,Wolfgang A. Schulz,A. Jay Gandolfi,Margaret R. Karagas,Teresa A. Zimmers,Mercè Jordà,P.A. Bejarano,Anthony J. Capobianco,David J. Robbins	41
15	Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cellsbreakdown → 2010 ·Science ·Anthony E. Boitano,Jian Wang,Russell D. Romeo,Laure C. Bouchez,Albert E. Parker,Sue Sutton,John R. Walker,Colin A. Flaveny,Gary H. Perdew,Michael S. Denison,Peter G. Schultz,Michael P. Cooke	772
16	Suppression of Cytokine-Mediated Complement Factor Gene Expression through Selective Activation of the Ah Receptor with 3′,4′-Dimethoxy-α-naphthoflavone 2010 ·Molecular Pharmacology ·Iain A. Murray,Colin A. Flaveny,Christopher Chiaro,Arun Sharma,(unknown),Jennifer C. Schroeder,Shantu Amin,William H. Bisson,Siva K. Kolluri,Gary H. Perdew	42
17	The Uremic Toxin 3-Indoxyl Sulfate Is a Potent Endogenous Agonist for the Human Aryl Hydrocarbon Receptor 2009 ·Biochemistry ·Jennifer C. Schroeder,Brett C. DiNatale,Iain A. Murray,Colin A. Flaveny,Qiang Liu,Elizabeth M. Laurenzana,Jyh Ming Lin,Stephen C. Strom,Curtis J. Omiecinski,Shantu Amin,Gary H. Perdew	263
18	Evidence for Ligand-Mediated Selective Modulation of Aryl Hydrocarbon Receptor Activity 2009 ·Molecular Pharmacology ·Iain A. Murray,José L. Quiles,Colin A. Flaveny,Brett C. DiNatale,(unknown),Krishne Gowda,Shantu Amin,Gary H. Perdew	80
19	The Aryl-hydrocarbon receptor does not require the p23 co-chaperone for ligand binding and target gene expression in vivo 2009 ·Toxicology Letters ·Colin A. Flaveny,Gary H. Perdew,Charles A. Miller	12
20	Ah receptor represses acute-phase response gene expression without binding to its cognate response element 2009 ·Laboratory Investigation ·Rushang D. Patel,Iain A. Murray,Colin A. Flaveny,Ann Kusnadi,Gary H. Perdew	81

About Colin A. Flaveny

Colin A. Flaveny is a scholar working on Health, Toxicology and Mutagenesis, Aging and Cancer Research, having authored 34 papers that have together received 2.8k indexed citations. Recurring topics across this work include Toxic Organic Pollutants Impact (8 papers), Cancer, Hypoxia, and Metabolism (5 papers) and Muscle Physiology and Disorders (4 papers). The work is most often cited by research in Biological Psychiatry (431 citations), Behavioral Neuroscience (174 citations) and Hematology (376 citations). Colin A. Flaveny has collaborated with scholars based in United States, India and Switzerland. Frequent co-authors include Gary H. Perdew, Iain A. Murray, Brett C. DiNatale, Jennifer C. Schroeder, Elizabeth M. Laurenzana, Curtis J. Omiecinski, Albert E. Parker, Russell D. Romeo, John R. Walker and Michael P. Cooke. Their work appears in journals such as Science, PLoS ONE and Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact